Article

New fluoroquinolones gaining on older versions

Newtown, PA-The new fourth-generation fluoroquinolones are showing rapid market growth as gatifloxacin 0.3% (Zymar, Allergan) posts strong gains after being on the market only a few weeks.

Related Videos
Dr. Analisa Arosemena discusses glaucoma at EyeCon 2024
Dr. Amir Ghanipour discusses light adjustable lenses for cataracts at EyeCon 2024
EyeCon 2024: Adam Wenick, MD, talks about myopic interventions across the lifespan
Related Content
Prevent Blindness officials discuss National Academies of Sciences, Engineering, and Medicine's report on myopia
October 6th 2024

Prevent Blindness officials discuss National Academies of Sciences, Engineering, and Medicine's report on myopia

Ehsan Sadri, MD, and Colin Green, PhD: How a noninvasive eye drop therapy could transform keratoconus care
September 23rd 2024

Innovation Series: What a noninvasive eye drop approach may mean for the future of keratoconus

Researchers: New AI model reaches clinical-expert-level accuracy in complex medical scans
October 4th 2024

Researchers: New AI model reaches clinical-expert-level accuracy in complex medical scans

Uncovering Neurotrophic Keratitis: Exploring Hidden Manifestations and Key Patient Demographics
August 30th 2024

Latest advances in X-linked retinitis pigmentosa: Optimizing diagnosis and developments in gene therapy

Aldeyra Therapeutics resubmits New Drug Application for reproxalap for the treatment of dry eye disease
October 3rd 2024

Aldeyra Therapeutics resubmits New Drug Application for reproxalap for the treatment of dry eye disease

Harrow relaunches triamcinolone acetonide injectable suspension
October 3rd 2024

Harrow relaunches triamcinolone acetonide injectable suspension

© 2024 MJH Life Sciences

All rights reserved.